New immune cell therapy tested for Tough-to-Treat blood cancer
NCT ID NCT05577000
Summary
This is an early-stage study to check the safety of a new treatment called anti-BCMA CAR-T cell therapy for people with multiple myeloma that has come back or stopped responding to other drugs. Doctors will collect a patient's own immune cells, modify them in a lab to better target the cancer, and then infuse them back. The main goals are to find a safe dose and see if the body can tolerate this new approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.